**Amendment to the Claims**

This listing of claims will replace all prior versions and listings of claims in the above-referenced application.

1-50. (cancelled)

51. (CANCELLED)

52. (currently amended) ~~The method of claim 51,~~ A method of treating a subject in need of treatment for malaria, wherein the subject is infected with a malaria parasite, the method comprising the step of: administering an antimalarial composition comprising a compound that is an inhibitor of fatty acid synthesis in the malaria parasite to the subject, wherein the inhibitor of fatty acid synthesis is a hydroxydiphenyl ether.

53. (previously presented) The method of claim 52, wherein the hydroxydiphenyl ether has general formula 2 given below wherein the two phenyl rings (I & II) are joined by an oxygen atom (X=O) and either $R_1$ or $R_2$ represents a hydroxy (OH) group with the other being a hydrogen atom, respectively, or both being hydroxy groups, and wherein $R_3$ to $R_{10}$ of the phenyl rings I and II are selected from the group consisting of: chlorine, bromine, iodine, hydrogen, hydroxyl groups, aldehyde groups, keto groups, and ester groups.




Formula 2

54. (previously presented) The method of claim 52, wherein the inhibitor of fatty acid synthesis is triclosan having formula 1 given below:




Formula 1

55. (previously presented) The method of claim 52, wherein the composition further comprises one or more known antimalarial agents and a pharmaceutically acceptable adjuvant, diluent, or carrier.

56. (previously presented) The method of claim 55, wherein the known antimalarial agent is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, anti-folates, artemisinin, artemether, and artesunate.

57. (previously presented) The method of claim 52, wherein the composition is administered by injection.

58. (previously presented) The method of claim 52, wherein the amount of the inhibitor of fatty acid synthesis administered is in the dosage range of 0.03 mg/kg to 100 mg/kg.

59. (previously presented) The method of claim 52, wherein the compound inhibits FabI (enoyl ACP reductase) in the malaria parasite.

60. (currently amended) The method of claim ~~51~~ 52, wherein the composition further comprises one or more known antimalarial agents and a pharmaceutically acceptable adjuvant, diluent, or carrier.

61. (previously presented) The method of claim 60, wherein the known antimalarial agent is selected from the group consisting of: quinine, atabrine, chloroquine, mefloquine, primaquine, anti-folates, artemisinin, artemether, and artesunate.

62. (currently amended) The method of claim ~~51~~52, wherein the inhibitor of fatty acid synthesis in the malaria parasite is an inhibitor of FabI (enoyl-ACP reductase).

63. (currently amended) The method of claim ~~51~~52, wherein the malaria parasite is *P. falciparum*.